| Kuriyama S, Kusaka Y, Fujimura M, et al. Prevalence and clinicoepidemiological features of moyamoya disease in Japan:findings from a nationwide epidemiological survey[J]. Stroke, 2008, 39:42-47.Scott RM, Smith ER. Moyamoya disease and moyamoya syndrome[J]. N Engl J Med, 2009, 360:1226-1237.Aoyagi M, Ogami K, Matsushima Y, et al. Human leukocyte antigen in patients with moyamoya disease[J]. Stoke, 1995, 26:415-417.Kamada F, Aoki Y, Narisawa A, et al. A genome-wide association study identifies RNF213 as the first Moyamoya disease gene[J]. J Hum Genet, 2011, 56:34-40.Liu W, Morito D, Takashima S, et al. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development[J]. PLoS One, 2011, 6:e22542. Li H, Zhang ZS, Liu W, et al. Association of a functional polymorphism in the MMP-3 gene with moyamoya disease in Chinese Han population[J]. Cerebrovasc Dis, 2010, 30:618-625. Wu Z, Jiang H, Zhang L, et al. Molecular analysis of RNF213 gene for moyamoya disease in the Chinese Han population[J]. PLoS One, 2012, 7:e48179.Kim SJ, Heo KG, Shin HY, et al. Association of thyroid autoantibodies with moyamoya-type cerebrovascular disease:a prospective study[J]. Stroke, 2010, 41:173-176.Li H, Zhang ZS, Dong ZN, et al. Increased thyroid function and elevated thyroid autoantibodies in pediatric patients with moyamoya disease[J]. Stroke, 2011, 42:1138-1139. Achrol AS, Guzman R, Lee M, et al. Pathophysiology and genetic factors in moyamoya disease[J]. Neurosurg Focus, 2009, 26:E4. Sigdel TK, Shoemaker LD, Chen R, et al. Immune response profiling identifies autoantibodies specific to Moyamoya patients[J]. Orphanet J Rare Dis, 2013, 21:45. Zou D, Zhao J, Zhang D, et al. Enhancement expression of bFGF in Chinese patients with Moyamoya disease[J]. Biomed Environ Sci, 2011, 24:74-80. Ni G, Liu W, Huang X, et al. Increased levels of circulating SDF-1α and CD34+ CXCR4+ cells in patients with moyamoya disease[J]. Eur J Neurol, 2011, 18:1304-1309. Lin R, Xie Z, Zhang J, et al. Clinical and immunopathological features of Moyamoya disease[J]. PLoS One, 2012, 7:e36386. Wakai K, Tamakoshi A, Ikezaki K, et al. Epidemiological features of moyamoya disease in Japan:findings from a nationwide survey[J]. Clin Neurol Neurosurg, 1997, 99:S1-5. Miao W, Zhao PL, Zhang YS, et al. Epidemiological and clinical features of Moyamoya disease in Nanjing, China[J]. Clin Neurol Neurosurg, 2010, 112:199-203. Guzman R, Lee M, Achrol A, et al. Clinical outcome after 450 revascularization procedures for moyamoya disease. Clinical article[J]. J Neurosurg, 2009, 111:927-935. Kim SK, Cho BK, Phi JH, et al. Pediatric moyamoya disease:An analysis of 410 consecutive cases[J]. Ann Neurol, 2010, 68:92-101. Duan L, Bao XY, Yang WZ, et al. Moyamoya disease in China:its clinical features and outcomes[J]. Stroke, 2012, 43:56-60.Gesang DZ, Zhang D, Zhao JZ, et al. Laser Doppler flowmeter study on regional cerebral blood flow in early stage after standard superficial temporal artery-middle cerebral artery bypass surgery for moyamoya disease[J]. Chin Med J (Engl), 2009, 122:2412-2418. Zhang J, Wang J, Geng D, et al. Whole-brain CT perfusion and CT angiography assessment of Moyamoya disease before and after surgical revascularization:preliminary study with 256-slice CT[J]. PLoS One, 2013, 8:e57595. Miyamoto S, Japan Adult Moyamoya Trial Group. Study design for a prospective randomized trial of extracranial-intracranial bypass surgery for adults with moyamoya disease and hemorrhagic onset--the Japan Adult Moyamoya Trial Group[J]. Neurol Med Chir (Tokyo), 2004, 44:218-219.Karzmark P, Zeifert PD, Tan S, et al. Effect of moyamoya disease on neuropsychological functioning in adults[J]. Neurosurgery, 2008, 62:1048-1052. Su SH, Hai J, Zhang L, et al. Assessment of cognitive function in adult patients with hemorrhagic moyamoya disease who received no surgical revascularization[J]. Eur J Neurol, 2013, 20:1081-1087. |
